Should I buy or sell AstraZeneca stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AZN shares. View AZN analyst ratings or view top-rated stocks .

What is AstraZeneca's stock price target for 2024?

9 equities research analysts have issued 1-year target prices for AstraZeneca's stock. Their AZN share price targets range from GBX 6,950 to £140. On average, they expect the company's share price to reach £118.95 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price. View analysts price targets for AZN or view top-rated stocks among Wall Street analysts .

How have AZN shares performed in 2023?

AstraZeneca's stock was trading at £112.18 at the beginning of 2023. Since then, AZN shares have decreased by 10.6% and is now trading at £100.24. View the best growth stocks for 2023 here .

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a dividend on Friday, July 28th. Stockholders of record on Thursday, August 10th will be given a dividend of GBX 71.80 per share on Monday, September 11th. This represents a yield of 0.67%. The ex-dividend date is Thursday, August 10th. The official announcement can be accessed at this link . Read our dividend analysis for AZN .

Is AstraZeneca a good dividend stock?

AstraZeneca (LON:AZN) pays an annual dividend of GBX 235 per share and currently has a dividend yield of 2.31%. The dividend payout ratio is 7,755.78%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for AZN .

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GSK (GSK) , NVIDIA (NVDA) , Gilead Sciences (GILD) , Intel (INTC) , Vodafone Group Public (VOD) , Advanced Micro Devices (AMD) , Alibaba Group (BABA) , Pfizer (PFE) , QUALCOMM (QCOM) and The Hain Celestial Group (HAIN) .

How do I buy shares of AstraZeneca?

Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

AstraZeneca Share Price, News & Analysis (LON:AZN)

£100.07

+106.99 (+1.08%)

(As of 05:26 PM ET)

Compare

Today's Range: 9,778
▼
£100.84
50-Day Range: 9,900
▼
£112.70
52-Week Range: 9,778
▼
£123.92

Volume: 1.32 million shs
Average Volume: 1.74 million shs
Market Capitalization: £155.11 billion

P/E Ratio: 3,302.64
Dividend Yield: 2.35%
Price Target: £118.95

Stock Analysis Analyst Forecasts Chart Competitors Dividend Headlines Insider Trades Sustainability

AstraZeneca MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.89 Rating Score
Upside/Downside: 18.7% Upside
£118.95 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: -2.35
Upright™ Environmental Score
News Sentiment: 0.22
Based on 11 Articles This Week
Insider Trading: Acquiring Shares
£10.17 M Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

3.4

Analyst's Opinion

Consensus Rating
AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of £118.95, AstraZeneca has a forecasted upside of 18.7% from its current price of £100.24.
Amount of Analyst Coverage
AstraZeneca has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

N/A

Short Interest

Short Interest
There is no current short interest data available for AZN.

0.8

Dividend Strength

Dividend Yield
AstraZeneca pays a meaningful dividend of 2.31%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
AstraZeneca does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of AstraZeneca is 7,755.78%. Payout ratios above 75% are not desirable because they may not be sustainable.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AstraZeneca has received a 55.59% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Osimertinib", "Olaparib", "SGLT2 inhibitors", "Durvalumab", "Asthma inhalers", and "Antiplatelet medication" products. See details.
Environmental Sustainability
The Environmental Impact score for AstraZeneca is -2.35.

2.9

News and Social Media Coverage

News Sentiment
AstraZeneca has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for AstraZeneca this week, compared to 1 article on an average week.
Search Interest
33 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.
MarketBeat Follows
3 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AstraZeneca insiders have bought more of their company's stock than they have sold. Specifically, they have bought £101,700 in company stock and sold GBX 0 in company stock.
Percentage Held by Insiders
Only 0.23% of the stock of AstraZeneca is held by insiders.
Percentage Held by Institutions
52.00% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of AstraZeneca is 3,308.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 116.26.
Price to Earnings Ratio vs. Sector
The P/E ratio of AstraZeneca is 3,308.25, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 101.51.
Price to Earnings Growth Ratio
AstraZeneca has a PEG Ratio of 0.49. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
AstraZeneca has a P/B Ratio of 4.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About AstraZeneca Stock (LON:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AZN Stock News Headlines

November 20, 2023 | marketbeat.com

3 stocks that crushed earnings estimates and still tanked (AZN)

Every earnings season, regardless of sector or industry, has its share of stocks that go down even after beating earnings expectations such as these stocks

November 29, 2023 | americanbankingnews.com

AstraZeneca's (AZN) "Buy" Rating Reaffirmed at Citigroup

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 29, 2023 | americanbankingnews.com

Jefferies Financial Group Lowers AstraZeneca (LON:AZN) Price Target to £125

November 24, 2023 | bizjournals.com

Lab Notes: AstraZeneca launches new business; Palvella receives key FDA designation

November 24, 2023 | americanbankingnews.com

AstraZeneca PLC (LON:AZN) Insider Michel Demare Acquires 1,000 Shares of Stock

November 23, 2023 | americanbankingnews.com

AstraZeneca (LON:AZN) Sets New 12-Month Low at $9,983.00

November 23, 2023 | americanbankingnews.com

Berenberg Bank Reiterates "Buy" Rating for AstraZeneca (LON:AZN)

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 22, 2023 | americanbankingnews.com

Barclays Reiterates Buy Rating for AstraZeneca (LON:AZN)

November 19, 2023 | americanbankingnews.com

AstraZeneca (LON:AZN) Earns Overweight Rating from JPMorgan Chase & Co.

November 17, 2023 | benzinga.com

US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges

November 17, 2023 | msn.com

AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer

November 10, 2023 | markets.businessinsider.com

AstraZeneca Lifts Annual Profit Outlook on Strong Drugs Portfolio

November 10, 2023 | msn.com

AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate

November 10, 2023 | msn.com

AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View

November 3, 2023 | msn.com

After a rocky October, are AstraZeneca shares now a buy?

October 31, 2023 | msn.com

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

October 31, 2023 | morningstar.com

AstraZeneca PLC ADR AZN

October 19, 2023 | markets.businessinsider.com

NVO, LLY, AZN: 3 “Strong Buy” Stocks to Bet on Weight-Loss Drugs

October 16, 2023 | benzinga.com

AstraZeneca's Tagrisso-Chemo Combo Under FDA Priority Review For Most Common Form Of Lung Cancer

October 4, 2023 | msn.com

AstraZeneca Agrees to a $425 Million Settlement in U.S. Lawsuits

September 26, 2023 | finance.yahoo.com

The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca

September 21, 2023 | marketwatch.com

AstraZeneca PLC ADR outperforms competitors despite losses on the day

September 15, 2023 | msn.com

Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More

September 15, 2023 | reuters.com

AstraZeneca succession sickness demands urgent fix

September 14, 2023 | finance.yahoo.com

AstraZeneca PLC (LON:AZN) Shares Could Be 36% Below Their Intrinsic Value Estimate

See More Headlines

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/11 Dividend: 8/10/2023
Dividend Payable: 9/11/2023
Today: 11/29/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Drug Manufacturers - General
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:AZN
CUSIP: N/A
CIK: N/A
Web: www.astrazeneca.com
Phone: +44-20-73045000
Fax: N/A
Employees: 83,500
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: £118.95
High Stock Price Target: £140
Low Stock Price Target: GBX 6,950
Potential Upside/Downside: +18.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): GBX 3.03
Trailing P/E Ratio: 3,310.23
Forward P/E Ratio: 14.85
P/E Growth: 0.49
Net Income: £5.90 billion
Net Margins: 13.10%
Pretax Margin: N/A
Return on Equity: 16.32%
Return on Assets: 9.23%

Debt

Debt-to-Equity Ratio: 79.40
Current Ratio: 0.79
Quick Ratio: 0.59

Sales & Book Value

Annual Sales: £44.99 billion
Price / Sales: 3.46
Cash Flow: GBX 257.90 per share
Price / Cash Flow: 38.89
Book Value: GBX 2,401 per share
Price / Book: 4.18

Miscellaneous

Outstanding Shares: 1,550,000,000
Free Float: N/A
Market Cap: £155.47 billion
Optionable: Not Optionable
Beta: 0.19

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Pascal Soriot D.V.M. (Age 64)
M.B.A., CEO & Executive Director
Comp: $4.78M
Dr. Aradhana Sarin M.D. (Age 48)
CFO & Executive Director
Comp: $2.73M
Ms. Pam P. Cheng (Age 52)
EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Mr. Andrew P. Barnett
Head of Investor Relations
Mr. Jeffrey Pott
CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Gonzalo Vina
Head of Global Media Relations
Dr. Menelas Pangalos Ph.D. (Age 56)
EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
Dr. Ruud Dobber Ph.D.
Executive Vice-President of BioPharmaceuticals Business Unit
Dr. Susan Mary Galbraith M.D. (Age 57)
Ph.D., Executive Vice President of Oncology Research & Development
Mr. Leon Wang
Executive VP of International & China President

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AstraZeneca was last updated on Thursday, November 16, 2023 at 12:00 AM.

Pros

Here are some ways that investors could benefit from investing in AstraZeneca PLC:

AstraZeneca PLC is a biopharmaceutical company that focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AstraZeneca PLC has a strong track record of innovation and research in the pharmaceutical industry.
The company has a diverse portfolio of products, which helps to mitigate risks associated with individual products.
AstraZeneca PLC has a global presence and operates in multiple markets, providing opportunities for growth and expansion.
The recent developments and advancements in AstraZeneca PLC's pipeline of drugs indicate potential for future success and revenue growth.

Cons

Investors should be bearish about investing in AstraZeneca PLC for these reasons:

The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which may impact AstraZeneca PLC's ability to bring new drugs to market.
There is a risk of patent expirations for some of AstraZeneca PLC's key products, which could lead to increased competition and loss of market share.
Changes in healthcare policies and regulations, both domestically and internationally, may affect the pricing and reimbursement of AstraZeneca PLC's products.
Investors should consider the potential impact of currency fluctuations on AstraZeneca PLC's financial performance, as the company operates globally.
It is important for investors to monitor the current stock price of AstraZeneca PLC and evaluate its valuation in relation to industry peers and market trends.

AZN Stock Analysis - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AZN shares.
View AZN analyst ratings or view top-rated stocks.
What is AstraZeneca's stock price target for 2024?: 9 equities research analysts have issued 1-year target prices for AstraZeneca's stock. Their AZN share price targets range from GBX 6,950 to £140. On average, they expect the company's share price to reach £118.95 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price.
View analysts price targets for AZN or view top-rated stocks among Wall Street analysts.
How have AZN shares performed in 2023?: AstraZeneca's stock was trading at £112.18 at the beginning of 2023. Since then, AZN shares have decreased by 10.6% and is now trading at £100.24.
View the best growth stocks for 2023 here.
How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?: AstraZeneca announced a dividend on Friday, July 28th. Stockholders of record on Thursday, August 10th will be given a dividend of GBX 71.80 per share on Monday, September 11th. This represents a yield of 0.67%. The ex-dividend date is Thursday, August 10th. The official announcement can be accessed at this link.
Read our dividend analysis for AZN.

Is AstraZeneca a good dividend stock?: AstraZeneca (LON:AZN) pays an annual dividend of GBX 235 per share and currently has a dividend yield of 2.31%. The dividend payout ratio is 7,755.78%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for AZN.
What other stocks do shareholders of AstraZeneca own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group Public (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).
How do I buy shares of AstraZeneca?: Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:AZN) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AstraZeneca Share Price, News & Analysis (LON:AZN)

AstraZeneca MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AstraZeneca Stock (LON:AZN)

AZN Stock Price History

AZN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

Pros

Cons

AZN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™